Potential of Osteoblastic Cells Derived from Bone Marrow and Adipose Tissue Associated with a Polymer/Ceramic Composite to Repair Bone Tissue
- 454 Downloads
One of the tissue engineering strategies to promote bone regeneration is the association of cells and biomaterials. In this context, the aim of this study was to evaluate if cell source, either from bone marrow or adipose tissue, affects bone repair induced by osteoblastic cells associated with a membrane of poly(vinylidene-trifluoroethylene)/barium titanate (PVDF-TrFE/BT). Mesenchymal stem cells (MSC) were isolated from rat bone marrow and adipose tissue and characterized by detection of several surface markers. Also, both cell populations were cultured under osteogenic conditions and it was observed that MSC from bone marrow were more osteogenic than MSC from adipose tissue. The bone repair was evaluated in rat calvarial defects implanted with PVDF-TrFE/BT membrane and locally injected with (1) osteoblastic cells differentiated from MSC from bone marrow, (2) osteoblastic cells differentiated from MSC from adipose tissue or (3) phosphate-buffered saline. Luciferase-expressing osteoblastic cells derived from bone marrow and adipose tissue were detected in bone defects after cell injection during 25 days without difference in luciferin signal between cells from both sources. Corroborating the in vitro findings, osteoblastic cells from bone marrow combined with the PVDF-TrFE/BT membrane increased the bone formation, whereas osteoblastic cells from adipose tissue did not enhance the bone repair induced by the membrane itself. Based on these findings, it is possible to conclude that, by combining a membrane with cells in this rat model, cell source matters and that bone marrow could be a more suitable source of cells for therapies to engineer bone.
KeywordsAnimal model Bone Mesenchymal stem cells Bone marrow Adipose tissue
Fabiana Rosseto de Moraes, Fabíola Singaretti de Oliveira, Milla Sprone Tavares, Roger Rodrigo Fernandes and Sebastião Carlos Bianco are acknowledged for their technical assistance during the experiments.
This research was supported by the National Council of Technological and Scientific Development (Grant # 456871/2013-6, CNPq - Brazil).
Compliance with Ethical Standards
Conflict of interest
Gileade P. Freitas, Helena B. Lopes, Adriana L. G. Almeida, Rodrigo P. F. Abuna, Rossano Gimenes, Lucas E. B. Souza, Dimas T. Covas, Marcio M. Beloti and Adalberto L. Rosa declare that they have no conflict of interest associated with this study and there has been no financial support that could have influenced our outcomes.
Human and Animal Rights and Informed Consent
All applicable international, national and/or institutional guidelines for the care and use of animals were followed. The Committee of Ethics in Animal Research of the School of Dentistry of Ribeirão Preto, University of São Paulo approved all animal procedures performed during the experiments.
- 3.Eap S, Keller L, Schiavi J, Huck O, Jacomine L, Fioretti F, Gauthier C, Sebastian V, Schwinté P, Benkirane-Jessel N (2015) A living thick nanofibrous implant bifunctionalized with active growth factor and stem cells for bone regeneration. Int J Nanomedicine 10:1061–1075PubMedPubMedCentralGoogle Scholar
- 6.Gimenes R, Zaghete MA, Bertolini M, Varela JA, Coelho LO, Silva NF Jr (2004) Composites PVDF-TrFE/BT used as bioactive membranes for enhancing bone regeneration. In: Bar-CohenY, editor. Proceedings of SPIE, Smart Structures and Materials, Vol. 5385. SPIE, Bellinghan, WA, pp 539–547Google Scholar
- 14.Rebelatto CK, Aguiar AM, Moretão MP, Senegaglia AC, Hansen P, Barchiki F, Oliveira J, Martins J, Kuligovski C, Mansur F, Christofis A, Amaral VF, Brofman PS, Goldenberg S, Nakao LS, Correa A (2008) Dissimilar differentiation of mesenchymal stem cells from bone marrow, umbilical cord blood, and adipose tissue. Exp Biol Med (Maywood) 233:901–913CrossRefGoogle Scholar
- 19.Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, Deans R, Keating A, Prockop DJ, Horwitz E (2006) Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 8:315–317CrossRefPubMedGoogle Scholar
- 27.Lebouvier A, Poignard A, Cavet M, Amiaud J, Leotot J, Hernigou P, Rahmouni A, Bierling P, Layrolle P, Rouard H, Chevallier N (2015) Development of a simple procedure for the treatment of femoral head osteonecrosis with intra-osseous injection of bone marrow mesenchymal stromal cells: study of their biodistribution in the early time points after injection. Stem Cell Res Ther 6:68CrossRefPubMedPubMedCentralGoogle Scholar
- 28.Detante O, Moisan A, Dimastromatteo J, Richard MJ, Riou L, Grillon E, Barbier E, Desruet MD, De Fraipont F, Segebarth C, Jaillard A, Hommel M, Ghezzi C, Remy C (2009) Intravenous administration of 99mTc-HMPAO-labeled human mesenchymal stem cells after stroke: in vivo imaging and biodistribution. Cell Transplant 18:1369–1379CrossRefPubMedGoogle Scholar
- 30.Stockmann P, Park J, von Wilmowsky C, Nkenke E, Felszeghy E, Dehner JF, Schmitt C, Tudor C, Schlegel KA (2012) Guided bone regeneration in pig calvarial bone defects using autologous mesenchymal stem/progenitor cells—a comparison of different tissue sources. J Craniomaxillofac Surg 40:310–320CrossRefPubMedGoogle Scholar